Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083706 | 1.00 | TRPV1 (0.47) | TRPV1ALDH1A1MEN1KMT2ASPHK2 | |
| SCHEMBL1083713 | 0.91 | TACR1 (0.39) | TRPV1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL1085071 | 0.91 | TACR1 (0.39) | TRPV1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL1085147 | 0.90 | KDM1A (0.41) | TRPV1ALDH1A1SPHK2SPHK1CHRM3 | |
| SCHEMBL1083711 | 0.90 | KDM1A (0.41) | TRPV1ALDH1A1SPHK2SPHK1CHRM3 | |
| SCHEMBL1083712 | 0.89 | TRPV1 (0.46) | TRPV1ALDH1A1MEN1KMT2ASPHK2 | |
| SCHEMBL1085607 | 0.89 | TRPV1 (0.46) | TRPV1ALDH1A1MEN1KMT2ASPHK2 | |
| SCHEMBL1420734 | 0.87 | GRIN2B (0.47) | TRPV1ALDH1A1MEN1KMT2ASPHK2 | |
| SCHEMBL1420737 | 0.87 | GRIN2B (0.47) | TRPV1ALDH1A1MEN1KMT2ASPHK2 | |
| SCHEMBL1085077 | 0.86 | CCR5 (0.42) | CHRM3CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | claimed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | claimed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | TRPV1 196/4885ALDH1A1 1202/4885MEN1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.